99.3% of the 1,088 events allegedly attributed to vaccines and immunizations (ESAVI) reported to the Integrated Health Information System of Argentina (SIISA) since the start of the National Vaccination Campaign against the coronavirus, on December 29, ” they were mild and moderate, “it was reported today.
This is specified in the Second Vaccine Safety Surveillance Report, carried out by the Ministry of Health in conjunction with the National Commission for Vaccine Safety, and released today, which indicates that, after the application of 39,599 doses in 22 of the 24 In the jurisdictions of the country, 1,088 cases of presumed reactions to inoculation, moderate or mild, were reported practically in their entirety.
“39.7% of the ESAVIs reported correspond to people with fever, headache and / or myalgia that started 6 to 8 hours after vaccination”, indicates the report, which remarks that “99.3% of the reported events they were mild and moderate. “
According to the report, 31.1% of the events were headaches and myalgias; 10.2% fever; 7.2% a local reaction at the injection site and 1.3% fever with gastrointestinal symptoms.
Only 1.2% had mild allergies; 0.6% lipothymia, the same gastrointestinal symptoms and 0.2% drowsiness.
For people who received the vaccine, it is recommended to consult the nearest health center in case symptoms appear after the inoculation.
It was also reported that, although vaccination is contraindicated in lactating women, the administration of the vaccine should not imply stopping it.
Regarding the evaluation of vaccinated people who report symptoms after the application of the dose, the report recommends “carrying out a complete clinical evaluation, reporting the case as ESAVI”.
“Given the detection of symptoms such as fever, headache or flu-like onset within 24 to 48 hours after vaccination, it is recommended to indicate symptomatic treatment with paracetamol with home rest and isolation,” says the report.
The report highlights that the notification can be made by any member of the health team and must be done within the first 24 hours, in cases of serious ESAVI, and within the first week in the rest of the non-serious events.
If symptoms persist for more than 24 hours, it is advisable to make a new consultation and consider its study if it constitutes the definition of a suspected case of Covid-19.
“For the second dose, in the cases that presented mild and moderate ESAVI, it is indicated that these people must complete the vaccination schedule with a minimum interval of 21 days,” the report adds.
Florencia Bruggesser, member of the board of directors of the Argentine Society of Vaccination and Epidemiology (SAVE), pointed out in dialogue with Télam that mild and moderate reactions occur “in almost all vaccines” and that now the emphasis is on “notifying everything symptom that appears after vaccination such as fever or headache ”and“ any event that is not associated that coincides temporarily ”with the inoculation.
“If a person had an accident or fainted, they are notified to see if it has to do with vaccination; it is being studied whether it is associated with the vaccine “, he explained and added:” When it is a new vaccine, everything is analyzed “for that reason an exhaustive surveillance is being carried out.
In agreement with the reactions Bruggesser affirmed that “it is expected; we are looking at it with the magnifying glass. We are seeing that it is 1% of those vaccinated; it is completely expected. If we did the same with the flu vaccine we would have a similar result ”.
The infectious disease doctor clarified that with “the vaccines on the calendar, such as the triple bacterial vaccine, they are not notified if the events are mild or moderate, but in the case of an infection that requires antibiotics.”
“Every year 1,500 mild and moderate cases and some serious cases are reported in the surveillance system,” he said.
He specified that “the events occur 6 or 8 hours after vaccination and some may appear a month later.”
He stressed that in the places where the vaccine is being applied “it was well accepted and even some people without notification are calling to receive it.”
“We are seeing that in each jurisdiction it is being carried out within the expected and progress is being made in other areas that have contact with infected people,” he said.
Spokesmen for the health portfolio had pointed out last week that the reactions reported after the application of the vaccine were “mild and moderate, did not require hospitalization and are within the normal parameters of any vaccine.”
They reported that in the application of the first 32,013 doses there were 317 cases of mild reactions after vaccination, among health personnel in Argentina, which were reported in the Federal Register of Nominal Vaccination (NoMiVac).
Sources from the Ministry of Health told Télam on that occasion that the preparation of this type of study was planned within the strategic planning for the follow-up of events related to immunization.
In this context, the Minister of Health, Ginés González García, rejected on January 2 the “false information published” in “the media and social networks” about the alleged negative effects of the Gamaleya vaccine, and assured that only ” has reported 1% of Esavi (events supposedly attributed to vaccination and immunization) “.
González García clarified that, “of the 317 reported cases, 99.3% were classified as mild or moderate, and the presence of fever, headache or muscle pain, as a single or combined symptom, represented 80% of the total events reported “.
In this regard, Ministry spokespersons explained to this agency that, so far, “the records in Argentina coincide with the phase 1 and 2 trials in Russia”, and that “the adverse effects are as expected.”